Business Wire

CA-THE-OPEN-GROUP

6.1.2022 10:02:04 CET | Business Wire | Press release

Share
Energistics Becomes an Affiliate of The Open Group® Following Completion of Governance Transition

Effective January 1st, Energistics Consortium, Inc. is now an affiliate of The Open Group®, a global consortium that enables the achievement of business objectives through technology standards. Energistics remains a separate entity, with The Open Group assuming control of Energistics operations, in a move which will enable broader community access, more efficient collaboration, and stronger standards evolution in line with the global energy transition.

Having proudly served the industry for over thirty years, Energistics is also a long-standing member of The Open Group OSDU™ Forum, and in October 2018 became the first non-operator company to be invited to join the Forum. Its WITSML , RESQML , PRODML , and ETP standards have become universal in the industry and form a critical component of the OSDU Data Platform.

Development will continue in Energistics Special Interest Groups (SIGs) to ensure the standards remain a vibrant part of the Energy community. Most recently, Energistics Transfer Protocol v1.2 was released in September 2021, and a consolidated Release Candidate for new versions of RESEQML, PRODML, and WITSML was made available in December 2021.

This work will support both the wider industry and the ongoing development of the OSDU Data Platform and standards for analyzing legacy subsurface energy data as well as new energy data from wind, geothermal, hydrogen, photovoltaic sources, and carbon capture, utilization, and storage data sources.

“As Energistics starts an exciting new chapter in its development, we want to thank the more than 3,500 upstream subject matter experts, from over 115 member companies, who have contributed to its development over the last thirty years,” said Ross Philo, CEO of Energistics. “We are also particularly grateful to our operational staff, who have served the industry with outstanding dedication. They have ensured a smooth transition for our members, and we wish them all the best in their next adventure.”

Today’s transition of governance reflects the significant overlap between Energistics and The Open Group OSDU Forum, with 42 of the 220 current Forum members also being Energistics members. Retaining its own board, the work of Energistics will now be overseen by members of both organizations alongside The Open Group itself.

“The relationship between Energistics and The Open Group has been a long and fruitful one, and this is the right next step for our organizations,” adds Steve Nunn, CEO and President of The Open Group. “Bringing the knowledge and capabilities of The Open Group OSDU Forum and the Energistics SIGs closer together means that we will continue to lead the charge in data exchange standards for the industry, while also opening doors to a broader community for both organizations. We are committed to ensuring that the Energistics standards continue to evolve, thrive, and enable cross-discipline integration of industry data.”

- ENDS -

About Energistics

Energistics is the leading upstream oil and gas industry's data standards body. We are a global, non-profit consortium established over 30 years ago to bring together industry professionals in a neutral and collaborative environment to develop and deploy open data exchange standards and to address oil and gas information sharing challenges. Our members consist of international and nationalized oil companies, oilfield service companies, hardware and software vendors, system integrators, regulatory agencies, and the global standards user community. For more information, visit our website at www.energistics.org .

About The Open Group

The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 850 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .

About The Open Group OSDU Forum

The Open Group OSDU Forum is developing the Open-Source Software OSDU Data Platform and associated standards that enables the Energy industry to develop the transformational technology implementation to support the world's changing Energy needs. The Open Group OSDU Forum has over 225 member organizations and over 1900 subscribers worldwide. Membership in The Open Group OSDU Forum is available to all energy stakeholders including international and nationalized oil companies, new energy providers, application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found at www.osduforum.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye